Vitiligo-like lesions occur with an incidence of up to 25% under anti-PD1 (e.g., pembrolizumab [103] and nivolumab [104]), PDL1 (e.g., atezolizumab), and CTLA4 (e.g., ipilimumab) treatments that target immune privilege checkpoints for advanced melanoma and other cancers [105,106]. This evidence concerns the gene CD274 and melanoma.